Roche Gets CE Mark for Rapid Antigen Test Distinguishing COVID-19 From Flu A/B

Roche has received a CE mark for its rapid antigen test that can distinguish between the SARS-CoV-2 virus that causes COVID-19, and influenza A and B.

The test kit, which delivers results in less than 30 minutes, works with Roche’s Navify Pass software, enabling individuals and healthcare professionals to store and share their test results and vaccine status. Results from the test are available in less than 30 minutes.

The company said it intends to file for Emergency Use Authorization from the FDA early in the new year.